Search Results 1301-1310 of 19370 for hemoglobin

1. Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency - Mayo Clinic

   Hemoglobin > 9.0 g/dL and < 13.5 g/dL (females) or <15.0 g/dL (males) within 28 days of randomization;; Serum ferritin < 100 ng/mL or 100 to 300 ng/mL with ...

2. Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer - Mayo Clinic

   Hemoglobin ≥ 8.0 g/dl based upon CBC/differential (Note: The use of transfusion or other intervention to achieve hemoglobin [Hgb] ≥ 8.0 g/dl is acceptable) ...

3. Radiation Therapy with Durvalumab or Cetuximab to Treat Patients with Locoregionally Advanced Head and Neck Cancer who Cannot Take Cisplatin - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] ≥ 9.0 g/dl is acceptable) (within 14 days prior to ...

4. Intestinal Permeability and Gastroparesis - Clinical Trials

   Patients with uncontrolled diabetes mellitus (hemoglobin A1C > 10). Patients with prior surgery to the esophagus, stomach or duodenum. Patients taking ...

5. Impact Of Estradiol Addback - Mayo Clinic

   ... hemoglobin <12.0 gm/dL; Drug or alcohol abuse, psychosis, depression, mania or severe anxiety;; Acute or chronic organ-system disease;; Endocrinopathy, other ...

6. A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma - Mayo Clinic

   Hemoglobin ≥ 9 g/dL;; ANC ≥ 1.5 x 10^9/L;; Platelet count ≥ 75 x 10^9/L. Serum creatinine ≥ ULN; or estimated creatinine clearance ≥ 50 mL/min by ...

7. CY 6031 Study Will Evaluate the Effects of Treatment With Aficamten (CK-3773274) Over a 24-week Period on Cardiopulmonary Exercise Capacity and Health Status in Patients With Symptomatic oHCM - Mayo Clinic

   - Hemoglobin ≥10g/dL at screening. - Respiratory exchange ratio (RER) ≥1.05 and pVO2 <80% predicted on the screening CPET per the core laboratory ...

8. Efficacy, Safety, And Tolerability Study Of Lunsekimig Compared With Placebo In Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized By An Eosinophilic Phenotype PERSEPHONE - Mayo Clinic

   Hemoglobin <10 g/100 mL for male and <9 g/100 mL for female. Neutrophils <1500/μL (<1000/μL for those of African descent). Platelets <100 000/μL. Creatinine ...

9. Subarachnoid hemorrhage - Doctors and departments - Mayo Clinic

   Find out more about diagnosis and treatment options for this bleeding in the brain.

10. A Study of the Efficacy and Safety of Belimumab Compared to Placebo in Adults With Systemic Sclerosis Associated Interstitial Lung Disease - Mayo Clinic

    mixed connective tissue disease, as determined by the investigator. 3. FVC ≤45% of predicted, or a DLco (corrected for hemoglobin) ≤40% of predicted or